FIRST REPORT OF METALLO-β-LACTAMASES PRODUCING Enterobacter spp. STRAINS FROM VENEZUELA

Primer reporte de cepas de Enterobacter spp productoras de metalobetalactamasas de Venezuela

Abstracts

Clinical strains of Enterobacter were isolated from Cumana's Central Hospital in Venezuela, and classified as E. cloacae (21), E. aerogenes(7), E. intermedium (1), E. sakazakii (1) and three unclassified. The strains showed high levels of resistance, especially to SXT (58.1%), CRO (48.8%), CAZ (46.6%), PIP (46.4%), CIP (45.2%) and ATM (43.3%). This is the first report for South America of bla_VIM-2 in two E. cloacae and one Enterobacter sp., which also showed multiple mechanisms of resistance. Both E. cloacaeshowed bla_TEM-1, but only one showed bla_CTX-M-15 gene, while no bla_SHV was detected.

Carbapenemase; Metallobetalactamase; VIM; Enterobacter ; Carbapenems

Cepas clínicas de Enterobacter fueron aisladas del Hospital central de Cumaná en Venezuela, y se clasificaron como E. cloacae (21), E. aerogenes(7), E. intermedium (1), E. sakazakii (1) y 3 sin clasificar. Las cepas mostraron altos niveles de resistencia, especialmente a SXT (58.1%), CRO (48.8%), CAZ (46.6%), PIP (46.4%), CIP (45.2%) and ATM (43.3%). Este es el primer reporte de América del Sur de bla_VIM-2 en dos cepas de E. cloacae y una de Enterobacter sp., las cuales también mostraron múltiples mecanismos de resistencia. Ambas especies de E. cloacae mostraron genes bla_TEM-1, pero solo una mostro el gen bla_CTX-M-15, mientras que bla_SHV no fue detectado.

INTRODUCTION

Species of the genus Enterobacter have been reported as an important source of intrahospital infections, especially those showing resistance to betalactams by the production of enzymes like extended spectrum beta-lactamases (ESBL) such as TEM, SHV, CTX, VEB, and carbapenemases such as VIM, KPC and GES¹⁴. This represents an important therapeutic challenge because of the few remaining treatment options, which gives rise to morbimortality and hospital expenses.

There are reports of Enterobacter strains producing metallo-β-lactamase (MBL) in different parts of the world, such as E. cloacae in Japan, Taiwan, Korea and Italy, as well as E. aerogenes in Japan and France². However, no MBL-producing strains of Enterobacter have been reported anywhere in the Americas, except in Mexico¹¹ and Argentina⁴.

METHODS

During August 2010 and March 2011, clinical strains of Enterobacter were isolated in the University Hospital Antonio Patricio de Alcala in Cumana, Venezuela. The use of the strains was approved by the patients or their relatives, according to the recommendations of the Bioethics and Biosecurity Committee of IIBCA, Universidad de Oriente, Cumana, Venezuela.

Isolated strains were inoculated in BHI broth, incubated for 12 hours at 37 °C and later in MacConkey agar for 24 hours, in order to evaluate the morphological characteristics of the colonies to verify purity. For the classification of Enterobacter species tests for the fermentation of glucose and lactose in Kligler medium, use of citrate, arginine and malonate, use of MIO, LIA, and methyl red and Voges-Proskauer medium according to standard biochemical tests established for Enterobacteriaceae⁸,¹⁶.

Antimicrobial susceptibility was assessed by Kirby-Bauer disk diffusion susceptibility test following the recommendations of the Clinical and Laboratory Standards Institute (CLSI). For tigecycline (TGC), we used the cutoff of the attached insert (Pfizer, INC).

Screening of extended spectrum beta-lactamases (ESBL), were carried out using the synergy effect between the antimicrobial disks CAZ, FEP, CRO, ATM and CTX surrounding AMC as well as the confirmatory test for ESBL was carried out using the combined disc test⁷. Additionally, in order to detect the presence of ESBL enzymes we used the modification suggested by SONG et al. (2007), in order to avoid the masking effect that a derepressed AmpC gene could produce¹⁵. For this, disks containing CAZ (30 µg) with and without clavulanic acid (10 µg) were added 3-aminophenyl boronic acid with a final amount of 400 µg.

The phenotypic detection of MBLs was carried out using IPM and MER disks on each side of a disk with ethylendiaminotetracetic acid-sodium mercaptoacetate (EDTA-SMA, 0.5 µmoles-3 µg) and the combined disc test (IMP, IMP-EDTA and MER, MER-EDTA)⁶.

DNA extraction was carried out using the Wizard Genomic DNA kit (Promega) from the strains isolated after incubation in LB broth for 20 hours at 37 °C. The bla_VIM gene was detected by PCR according to MENDEZ et al.¹⁰. Additionally, we detected the type 1 and 2 bla_VIM according to FIETT et al.³. The genes bla_CTX-M (EDELSTEIN et al.unpublished results, http://www.antibiotic.ru/en/pdfs/006-51.pdf), bla_TEM and bla_SHV¹² were also detected. Finally, in order to determine the clonality of the three Enterobacter strains showing a phenotype consistent with MBL by the IMP/MER/EDTA synergy test, we used ERIC-PCR¹³.

RESULTS

The 33 strains of Enterobacter isolated were classified as E. cloacae (21), E. aerogenes(7), E. intermedium (1), E. sakazakii (1) and three were not possible to classify.

Ten of the strains were from infections acquired outside the hospital and most of the intrahospitalary strains were isolated in ICU (5), internal medicine areas A and B (4), soft surgery hall (4), pediatric area (3) and neonatology (3).

Antimicrobial susceptibility tests show high levels of resistance in most of the strains, with resistance to SXT (58.1%), CRO (48.8%), CAZ (46.6%), PIP (46.4%), CIP (45.2%) and ATM (43.3%) being the highest (Fig. 1). However, all the strains were sensitive to TGC. Results of the synergy test between CAZ/FEP/CRO/CTX/ATM with AMC in 16 of the strains were compatible with ESBL enzymes. We found that these strains showed the typical phenotypic effect for ESBL enzymes when using the combined disc test as a confirmatory. Additionally, three of the Enterobacter strains (two E. cloacae and one Enterobactersp.) were resistant to cabapenems showing also synergy between IPM/MER and EDTA, typical of MBL enzymes (Table 1). ERIC-PCR patterns show no similarities among these strains. They showed resistance to multiple families of antibiotics (MDRs) and two of them also showed presence of ESBL by the synergy assay. These strains amplified for bla_VIM-2 fragments (801 bp). Furthermore, both strains of E. cloacae amplified the typical fragment of the bla_TEM gene (1080 bp), but only one of them amplified the fragment of the bla_CTX-M gene (543 bp), while no bla_SHV gene was detected.

Fig. 1
Antimicrobial susceptibility of the Enterobacterstrains isolated in the Cumana hospital of Venezuela. CAZ: ceftazidime, CRO: ceftriaxone, FEP: cefepime, ATM: aztreonam, IPM: imipenem, MER: meropenem, PIP: piperacillin, TZP: piperacillin/tazobactam, SXT: trimethoprim-sulfamethoxazole, GM: gentamicin, AK: amikacin, CIP: ciprofloxacin and TGC: tigecycline.

Table 1
Resistance pattern and epidemiological data of the three strains of Enterobacter showing bla_VIM type 2 MBLs

Species	Isolation date	Hospital area	Type of sample	Resistance pattern	Synergy tests	Detected genes
E. cloacae	August 2010	Soft Surgery	catheter	CAZ, FEP, IPM, MER, TZP, PIP, CRO, ATM, SXT, AK, GM	ESBL, MBL	blaVIM-2, blaTEM-1, blaCTX-M-15
Enterobacter sp.	March 2011	ICU	bronchial secretion	CAZ, FEP, IPM, MER, TZP, PIP, CRO, ATM, SXT, CIP	AmpC, MBL	bla VIM-2
E. cloacae	April 2011	Internal Medicine B	urine	CAZ, FEP, IPM, MER, TZP, PIP, CTX, ATM, SXT, CIP, AK	ESBL, MBL	blaVIM-2, blaTEM-1

• ESBL: extended-spectrum betalactamase, MBL: metallo-β-lactamase, AmpC: de-repression of the chromosomal AmpC gene. ICU: intensive care unit. Acronyms of antibiotic as shown in the legend of Fig. 1.

Sequencing of the fragment of the bla_VIMgene, amplified using primers for type 2, produced sequences 100% homologous to bla_VIM-2 reported in the GenBank in P. aeruginosa and other bacteria. Also, the sequences of the bla_TEM gene were 100% homologous to type 1 reported for many Enterobacteria. In addition, the fragment of the bla_CTX-M gene sequenced showed 100% homology with CTX-M-15 found in E. coli and other Enterobacteria.

DISCUSSION

According to our phenotypic tests, BLEA and ESBL-type of enzymes was very prevalent. On the other hand, we are not aware of previous reports of the presence of VIM-producing Enterobacter strain in any South American country. In Mexico, strains of E. cloacae have been shown to produce MBL¹¹. These strains produced bla_VIM-2 MBLs, the same type we found in this study. In Argentina, one strain of E. cloacae was reported containing bla_IMP gene, along with bla_PER and genes that confer resistance to aminoglycosides and quinolones⁴. This type of gene has been reported in Venezuela but only in strains of Pseudomonas aeruginosa and Klebsiella pneumoniae⁵,⁹. VIM-producing P. aeruginosa strains were previously found in Cumana hospital (ENSONY TOVAR & MARCOS DE DONATO, unpublished results). It seems very likely that the gene found in P. aeruginosa could have been transferred through mobile elements such as plasmid and/or integrons between these two species which are sharing the same environment, as previously reported¹⁴, making possible the spread of this gene to many other bacteria species causing infection in this hospital environment.

The presence of multiple mechanisms of resistance in the bacteria isolated in the Cumana hospital causing intrahospital infections, especially in species of Enterobacter, which have natural resistance to several antibacterial drugs, suggests that more efficient preventive measures must be put in place in this hospital to avoid the survival and transmission of these strains. However, all the strains were susceptible to tigecycline, making it a suitable treatment for infections caused by MBL-producing enzymes in this hospital. This result agrees with numerous reports describing the use of tigecycline to treat infections caused by multidrug resistant bacteria, including those producing carbapenemases¹⁴.

REFERENCES

• ¹
  Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, et al. Antimicrobial activity of tygecicline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis. 2006;56:437-44.
• ²
  Falcone M, Mezzatesta ML, Perilli M, Forcella C, Giordano A, Cafiso V, et al. Infections with VIM-1 metallo-beta-lactamase-producing Enterobacter cloacae and their correlation with clinical outcome. J Clin Microbiol. 2009;47:3514-9.
• ³
  Fiett J, Baraniak A, Mrówka A, Fleischer M, Drulis-Kawa Z, Naumiuk Ł, et al. Molecular epidemiology of acquired-metallo-beta-lactamase-producing bacteria in Poland. Antimicrob Agents Chemother. 2006;50:880-6.
• ⁴
  Gomez S, Rapoport M, Togneri A, Viegas-Caetano J, Faccone D, Corso A, et al. Emergence of metallo-β-lactamases in Enterobacteriaceae from Argentina. Diagn Microbiol Infect Dis. 2011;69:94-7.
• ⁵
  Guevara A, de Waard J, Araque M. Detección del gen blaVIM-2 en cepas de Pseudomonas aeruginosa productoras de metalo β-lactamasa aisladas en una unidad de cuidados intensivos en Ciudad Bolívar, Venezuela. Rev Chil Infect. 2009;26:336-41.
• ⁶
  Lee K, Lim Y, Yong D, Yum J, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-ß-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2003;41:4623-9.
• ⁷
  Lezameta L, Gonzáles-Escalante E, Tamariz JH. Comparación de cuatro metodos fenotipicos para la detección de beta-lactamasas de espectro extendido. Rev Peru Med Exp Salud Publica. 2010;27:345-51.
• ⁸
  MacFaddin JE. Biochemical tests for identification of medical bacteria. 3rd ed. Bloomington: Lippincott Williams & Wilkins; 2000.
• ⁹
  Marcano D, Pasterán F, Rapoport M, Faccone D, Ugarte C, Salgado N, et al. First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela. J Infect Dev Ctries. 2008;2:241-4.
• ¹⁰
  Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol. 2007;45:544-7.
• ¹¹
  Morfin-Otero R, Rodriguez-Noriega E, Deshpande LM, Sader HS, Castanheira M. Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in Mexico: report from the SENTRY Antimicrobial Surveillance Program. Microb Drug Resist. 2009;15:33-5.
• ¹²
  Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, et al. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother. 2003;47:2864-7.
• ¹³
  Reboli AC, Houston ED, Monteforte JS, Wood CA, Hamill RJ. Discrimination of epidemic and sporadic isolates of Acinetobacter baumannii by repetitive element PCR-mediated DNA fingerprinting. J Clin Microbiol. 1994;32:2635-40.
• ¹⁴
  Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. Dissemination and diversity of metallo-β-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents. 2005;25:57-61.
• ¹⁵
  Song W, Bae I, Lee YN, Lee CH, Lee SH, Jeong SH. Detection of extended-spectrum β-lactamases by using boronic acid as AmpC β-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol. 2007;45:1180-4.
• ¹⁶
  Winn WC, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, et al. Koneman's color atlas and textbook of diagnostic microbiology. 6th ed. Bloomington: Lippincott Williams & Wilkins; 2005.

Publication Dates

• Publication in this collection
  Jan-Feb 2014

History

• Received
  13 Dec 2012
• Accepted
  29 May 2013